The lack of significant enhancement of the anti-NUGC-4 effect by IFN-γ transduction may be due to that the amount of IFN-γ produced by iPS-ML/anti-HER2/IFN-γ was lower than the level to exert anti-cancer effect. The gene discussed is IFNG; the disease is cancer.